Maze Therapeutics, Inc. 4

CEO Jason V. Coloma sold 22,638 shares of Maze Therapeutics common stock for roughly $595,000, primarily to cover RSU-related tax withholding, and retained about 268,868 shares in total beneficial ownership.

On September 2 and 3, 2026, Maze Therapeutics, Inc. CEO Jason V. Coloma sold an aggregate 22,638 shares of the company’s common stock in open-market transactions at weighted average prices between roughly $25.77 and $27.12 per share, generating proceeds of about $595,000. According to the Form 4, these sales were made solely to cover tax withholding obligations arising from the vesting of restricted stock units, indicating they were administrative rather than discretionary portfolio sales. Following these trades, Coloma continued to hold 27,362 shares directly, plus indirect beneficial ownership of 18,151 shares through The Coloma 2021 Irrevocable Trust and 223,355 shares through the Coloma Family Trust, for total beneficial ownership of approximately 268,868 shares, which at the transaction price levels equates to roughly $7.1 million in value.

Filing Facts

CIK

1842295

Ticker

MAZE

Form

4

Source Type

fda

Accession

0001676170-26-000022

Alert Tier

6